Genmab — November 2019
-
Citi reiterates a Buy rating and DKK1,500.00 price target on Genmab -from StreetInsider.com
-
Rimelig stor omsætning på de første tre timer.
-
Drug repurposing - featuring ofatumumab https://www.pharmaceutical-technology.com/features/drug-repurposing-all-rounder/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
ser spændende ud - jeg er allerede all in men kan spæde til med CFDer